<DOC>
	<DOCNO>NCT01856439</DOCNO>
	<brief_summary>The study design assess long term tolerability ProSavin whether safe efficacious patient administer ProSavin PS1/001/07 study .</brief_summary>
	<brief_title>Long Term Safety Efficacy Study ProSavin Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>must meet inclusion criterion study PS1/001/07 willing LDOPA dosage reduced/withdrawn discretion investigator regular interval allow assessment ProSavin absence concomitant antiparkinsonian medication . affiliated French social security health care system ( Patients enrol France ) sign date write informed consent obtain patient and/or patient 's legally acceptable representative , applicable , accordance local regulation must treat ProSavin/Sham</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ProSavin</keyword>
	<keyword>Gene therapy</keyword>
</DOC>